ABOUT GRU JOIN
Christopher J. Kane, MD, FACS

Christopher J. Kane, MD, FACS

University of California, San Diego School of Medicine

La Jolla, California

Dr. Kane is the Dean of Clinical Affairs at the University of California San Diego School of Medicine, as well as the CEO of the UC San Diego Health Physician Group. A retired U.S. Navy captain and Desert Storm veteran, Dr. Kane received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his residency at the Naval Medical Center in Oakland, California. He specializes in prostate, kidney, bladder, and testicular cancer, and has published over 320 peer-reviewed articles and book chapters focused on urological cancers. He is also an expert in robotic prostatectomy, open and laparoscopic kidney cancer surgery, and bladder and testes cancer surgery. Dr. Kane serves on the National Comprehensive Cancer Network Prostate Cancer Management Guidelines Committee and has been a member of the American Association of Genitourinary Surgeons since 2014.

Disclosures:

Talks by Christopher J. Kane, MD, FACS

Germline Screening and Polygenic Risk Scores

Germline Screening and Polygenic Risk Scores

Posted by | Sep 2023

Christopher J. Kane, MD, FACS, provides a comprehensive overview of genetic testing in prostate cancer. He emphasizes the importance of distinguishing somatic mutations from germline mutations, and explains the concept of high-penetrance genomic syndromes.

Dr. Kane highlights that genetic testing can be done on various tissues, with cheek swabs and blood tests being the most common methods. He identifies common genetic changes, such as BRCA2, and mentions testing companies like Invitae, Color, and Foundation.

The discussion also covers the significance of single nucleotide polymorphisms (SNP) in non-coding regions of DNA and their role in inherited mutations. Dr. Kane discusses the criteria for testing, including personal or family history suggestive of an inherited syndrome, test validity, and its impact on patient care.

He underscores the relevance of genomic testing for advanced prostate cancer patients, as actionable therapeutics are available for those with DNA repair gene abnormalities. Dr. Kane refers to the Pritchard article, which revealed a higher frequency of genomic syndromes in men with metastatic prostate cancer than previously estimated. Dr. Kane concludes by acknowledging the limitations of family history and the superiority of SNP testing as a predictor of prostate cancer risk.

Read More
Management of the Primary in Locally Advanced and Oligometastatic Disease

Management of the Primary in Locally Advanced and Oligometastatic Disease

Posted by | Aug 2023

Christopher J. Kane, MD, FACS, discusses data regarding the management of the primary in locally advanced and oligometastatic prostate cancer. He reviews a study on the diagnostic accuracy of Gallium Ga 68 PSMA-11 injections used with a PET scan (68Ga-PSMA-11 PET) for pelvic nodal metastasis detection prior to radical prostatectomy (RP) and pelvic lymph node dissection. He explains that 68Ga-PSMA-11 PET is critical in the assessment of men with clinically localized high-risk prostate cancer and that many patients with negative PSMA scans and high-risk clinical features will have positive lymph nodes (N1) discoverable by 68Ga-PSMA-11 PET. 

Dr. Kane cites updated National Comprehensive Cancer Network (NCCN) Guidelines that include a recommendation not to omit a node dissection based on PSMA PET results. He reviews findings from both the SPCG-7/SFUO-3 trial and the National Cancer Data Base (NCDB) retrospective review, emphasizing the value of treating the prostate in N1 disease. Data from the VA Informatics and Computing Infrastructure (VINCI) database shows that androgen deprivation therapy (ADT) with radiotherapy was associated with improved prostate cancer-specific mortality (PCSM) among patients with prostate-specific antigen (PSA) levels <26 ng/mL and with improved all-cause mortality (ACM) among those same patients.  Dr. Kane points to a similar analysis of VINCI data on patients who had undergone RP that found, compared with non-definitive therapy, RP was associated with significantly better PCSM and ACM. Compared to radiotherapy, RP was not associated with a significant difference in PCSM or ACM. Dr. Kane cites data showing a significant metastasis-free survival advantage among patients with a first postoperative PSA <0.2 ng/mL, a finding that has since been replicated.  Finally, Dr. Kane emphasizes the value of treating the primary with T3 in high-risk disease, with T3 and N1 in prostate cancer patients, and with radiotherapy in low metastatic burden M1 disease. He explains the threshold of metastatic burden effect is not well known and there is a clinical trial underway exploring RP and radiotherapy in the M1 population with the current standard of care, and he reiterates that pathological N1 patients benefit from salvage IMRT/ADT.

Read More
Point-Counterpoint: Surgery vs. Brachytherapy for Intermediate and High-Risk Prostate Cancer – Surgery

Point-Counterpoint: Surgery vs. Brachytherapy for Intermediate and High-Risk Prostate Cancer – Surgery

Posted by | Jul 2023

Christopher J. Kane, MD, FACS, delivers an insightful presentation on the topic of surgery versus brachytherapy for intermediate and high-risk prostate cancer. He begins by highlighting the importance of accurately defining high-risk disease and its implications for treatment outcomes.

While various definitions exist, Dr. Kane focuses primarily on high-risk disease characterized by a PSA over 20, Gleason sum of eight, and clinical stage T2C. Dr. Kane presents his viewpoint that surgery is the optimal treatment for well-selected patients with high-risk prostate cancer. He supports this assertion by discussing several key advantages of surgery over radiation therapy.

He emphasizes the benefits of improved pathologic staging and risk assessment that surgery offers. Additionally, he notes the effectiveness of adjuvant and early salvage therapy in curing many adverse pathologic patients. Moreover, surgery provides better local control and reduces the likelihood of ureteral obstructions and urinary procedures at progression.

Dr. Kane then presents comparative risk-adjusted mortality data from various studies. These analyses demonstrate that surgery significantly reduces cause-specific mortality compared to all forms of radiation therapy. The magnitude of the differences increases with disease risk, further underscoring the value of surgery for patients with higher risk disease.

This lecture is part of a Point-Counterpoint debate. Its opposing lecture is “Point-Counterpoint: Surgery vs. Brachytherapy for Intermediate and High-Risk Prostate Cancer–Radiation.

Read More
Racial Justice and Prostate Cancer

Racial Justice and Prostate Cancer

Posted by | Jul 2022

Christopher J. Kane, MD, FACS, the Dean of Clinical Affairs at the University of California San Diego School of Medicine, and the CEO of the UC San Diego Health Physician Group, discusses the role of race in prostate cancer mortality among Black men. Dr. Kane presents data showing that both the incidence and rate of death from prostate cancer are significantly higher in Black men, and that this ratio has remained consistent over time. Referencing the SEER database, Dr. Kane notes that Black men were twice as likely to die of prostate cancer. While there are claims that biologic differences between Black and White men are to blame for the rate of death, Dr. Kane points out that the genetic differences between Black men are similar to the genetic difference between White men. He further adds that inheritance patterns of Black Americans are highly variable and cannot be considered a homogenous biological construct. Beyond genetic factors, Dr. Kane mentions other possible causes for the disparity including environmental factors, care dynamics, care quality, and availability. He then reviews a study that analyzed three cohorts to determine whether Black race was associated with inferior prostate cancer outcomes if patients had similar access to care and standardized treatment. The results indicate that Black men were not at higher risk of prostate cancer mortality when they had access to better healthcare. He concludes that physicians can save nearly 4,000 Black men who would otherwise die of prostate cancer each year. Regardless of potential factors impacting disease risk and progression in Black men, Dr. Kane maintains that providing superb screening, detection, and treatment can reduce the observed racial difference in prostate cancer outcomes.

Read More
Panel Discussion on Integration of Stakeholders in Healthcare: Academic Urology

Panel Discussion on Integration of Stakeholders in Healthcare: Academic Urology

Posted by | May 2020

Christopher J. Kane, MD, FACS, Dean of Clinical Affairs at the University of California San Diego School of Medicine, discusses the role of academic institutions in supporting the wider urology community, using USCD as an example. He notes that the UC medical system is the 4th largest provider of healthcare in California and UCSD is the 8th producer of scientific output in life sciences of any institution globally, therefore contributing greatly to the medical field as a whole. USCD Urology provides numerous specific benefits to the greater urology community, including practitioners in LUGPAs and integrated practice systems. These benefits include subspecialty coordinated care, CME opportunities, principled defense and professional support, and a clinically integrated network, among others.

Read More

Join the GRU Community

- Why Join? -